Glucagon-like peptide 2 inhibits ghrelin secretion in humans

Matthias Banasch; Kerem Bulut; Dirk Hagemann; Henning Schrader; Jens Juul Holst; Wolfgang E Schmidt; Juris J Meier

doi:10.1016/j.regpep.2006.07.009

Glucagon-like peptide 2 inhibits ghrelin secretion in humans

Matthias Banasch, Kerem Bulut, Dirk Hagemann, Henning Schrader, Jens Juul Holst, Wolfgang E Schmidt, Juris J Meier

Endocrinology and Metabolism

15 Citationer (Scopus)

Abstract

INTRODUCTION: The growth hormone secretagogue receptor ligand ghrelin is known to play a pivotal role in the central nervous control of energy homeostasis. Circulating ghrelin levels are high under fasting conditions and decline after meal ingestion, but the mechanisms underlying the postprandial drop in ghrelin levels are poorly understood. In the present study we addressed, whether (1) exogenous GLP-2 administration decreases ghrelin levels and (2) what other endogenous factors are related to ghrelin secretion under fasting conditions.

PATIENTS AND METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 (2 pmol l(-1) min(-1)) or placebo over 120 min in the fasting state. Plasma concentrations of glucose, insulin, C-peptide, glucagon, intact GLP-2 and ghrelin were determined.

RESULTS: During the infusion of GLP-2, plasma concentrations of intact GLP-2 increased from 10.0+/-1.5 pmol/l to steady-state levels of 207.7+/-8.3 pmol/l (p < 0.0001). Administration of GLP-2 led to an approximately 10% reduction in ghrelin concentrations, whereas placebo administration was without an effect (p < 0.001). After cessation of the GLP-2 infusion, ghrelin levels returned to baseline values, and were no longer different from those in the placebo experiments. There was a strong inverse linear relationship between the fasting concentrations of ghrelin and the respective levels of glucose, insulin and C-peptide (r = 0.49, p < 0.01; r = 0.55, p < 0.01 and r = 0.59, p < 0.001, respectively). In contrast, there was no detectable association between fasting ghrelin levels and the ambient concentrations of glucagon or intact GLP-2.

CONCLUSIONS: GLP-2 inhibits ghrelin secretion in humans at plasma levels of approximately 200 pmol/l. However, the physiological importance of this effect appears to be minor compared to the actions of insulin and glucose.

Originalsprog	Engelsk
Tidsskrift	Regulatory Peptides
Vol/bind	137
Udgave nummer	3
Sider (fra-til)	173-8
Antal sider	6
ISSN	0167-0115
DOI	https://doi.org/10.1016/j.regpep.2006.07.009
Status	Udgivet - 10 dec. 2006

Adgang til dokumentet

10.1016/j.regpep.2006.07.009

Citationsformater

@article{d75ea773ba684aa8b12e55da7f4d0aaa,

title = "Glucagon-like peptide 2 inhibits ghrelin secretion in humans",

abstract = "INTRODUCTION: The growth hormone secretagogue receptor ligand ghrelin is known to play a pivotal role in the central nervous control of energy homeostasis. Circulating ghrelin levels are high under fasting conditions and decline after meal ingestion, but the mechanisms underlying the postprandial drop in ghrelin levels are poorly understood. In the present study we addressed, whether (1) exogenous GLP-2 administration decreases ghrelin levels and (2) what other endogenous factors are related to ghrelin secretion under fasting conditions.PATIENTS AND METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 (2 pmol l(-1) min(-1)) or placebo over 120 min in the fasting state. Plasma concentrations of glucose, insulin, C-peptide, glucagon, intact GLP-2 and ghrelin were determined.RESULTS: During the infusion of GLP-2, plasma concentrations of intact GLP-2 increased from 10.0+/-1.5 pmol/l to steady-state levels of 207.7+/-8.3 pmol/l (p < 0.0001). Administration of GLP-2 led to an approximately 10% reduction in ghrelin concentrations, whereas placebo administration was without an effect (p < 0.001). After cessation of the GLP-2 infusion, ghrelin levels returned to baseline values, and were no longer different from those in the placebo experiments. There was a strong inverse linear relationship between the fasting concentrations of ghrelin and the respective levels of glucose, insulin and C-peptide (r = 0.49, p < 0.01; r = 0.55, p < 0.01 and r = 0.59, p < 0.001, respectively). In contrast, there was no detectable association between fasting ghrelin levels and the ambient concentrations of glucagon or intact GLP-2.CONCLUSIONS: GLP-2 inhibits ghrelin secretion in humans at plasma levels of approximately 200 pmol/l. However, the physiological importance of this effect appears to be minor compared to the actions of insulin and glucose.",

keywords = "Adult, Blood Glucose, C-Peptide, Ghrelin, Glucagon, Glucagon-Like Peptide 2, Humans, Infusions, Intravenous, Insulin, Kinetics, Male, Peptide Hormones",

author = "Matthias Banasch and Kerem Bulut and Dirk Hagemann and Henning Schrader and Holst, {Jens Juul} and Schmidt, {Wolfgang E} and Meier, {Juris J}",

year = "2006",

month = dec,

day = "10",

doi = "10.1016/j.regpep.2006.07.009",

language = "English",

volume = "137",

pages = "173--8",

journal = "Regulatory Peptides",

issn = "0167-0115",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Glucagon-like peptide 2 inhibits ghrelin secretion in humans

AU - Banasch, Matthias

AU - Bulut, Kerem

AU - Hagemann, Dirk

AU - Schrader, Henning

AU - Holst, Jens Juul

AU - Schmidt, Wolfgang E

AU - Meier, Juris J

PY - 2006/12/10

Y1 - 2006/12/10

N2 - INTRODUCTION: The growth hormone secretagogue receptor ligand ghrelin is known to play a pivotal role in the central nervous control of energy homeostasis. Circulating ghrelin levels are high under fasting conditions and decline after meal ingestion, but the mechanisms underlying the postprandial drop in ghrelin levels are poorly understood. In the present study we addressed, whether (1) exogenous GLP-2 administration decreases ghrelin levels and (2) what other endogenous factors are related to ghrelin secretion under fasting conditions.PATIENTS AND METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 (2 pmol l(-1) min(-1)) or placebo over 120 min in the fasting state. Plasma concentrations of glucose, insulin, C-peptide, glucagon, intact GLP-2 and ghrelin were determined.RESULTS: During the infusion of GLP-2, plasma concentrations of intact GLP-2 increased from 10.0+/-1.5 pmol/l to steady-state levels of 207.7+/-8.3 pmol/l (p < 0.0001). Administration of GLP-2 led to an approximately 10% reduction in ghrelin concentrations, whereas placebo administration was without an effect (p < 0.001). After cessation of the GLP-2 infusion, ghrelin levels returned to baseline values, and were no longer different from those in the placebo experiments. There was a strong inverse linear relationship between the fasting concentrations of ghrelin and the respective levels of glucose, insulin and C-peptide (r = 0.49, p < 0.01; r = 0.55, p < 0.01 and r = 0.59, p < 0.001, respectively). In contrast, there was no detectable association between fasting ghrelin levels and the ambient concentrations of glucagon or intact GLP-2.CONCLUSIONS: GLP-2 inhibits ghrelin secretion in humans at plasma levels of approximately 200 pmol/l. However, the physiological importance of this effect appears to be minor compared to the actions of insulin and glucose.

AB - INTRODUCTION: The growth hormone secretagogue receptor ligand ghrelin is known to play a pivotal role in the central nervous control of energy homeostasis. Circulating ghrelin levels are high under fasting conditions and decline after meal ingestion, but the mechanisms underlying the postprandial drop in ghrelin levels are poorly understood. In the present study we addressed, whether (1) exogenous GLP-2 administration decreases ghrelin levels and (2) what other endogenous factors are related to ghrelin secretion under fasting conditions.PATIENTS AND METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 (2 pmol l(-1) min(-1)) or placebo over 120 min in the fasting state. Plasma concentrations of glucose, insulin, C-peptide, glucagon, intact GLP-2 and ghrelin were determined.RESULTS: During the infusion of GLP-2, plasma concentrations of intact GLP-2 increased from 10.0+/-1.5 pmol/l to steady-state levels of 207.7+/-8.3 pmol/l (p < 0.0001). Administration of GLP-2 led to an approximately 10% reduction in ghrelin concentrations, whereas placebo administration was without an effect (p < 0.001). After cessation of the GLP-2 infusion, ghrelin levels returned to baseline values, and were no longer different from those in the placebo experiments. There was a strong inverse linear relationship between the fasting concentrations of ghrelin and the respective levels of glucose, insulin and C-peptide (r = 0.49, p < 0.01; r = 0.55, p < 0.01 and r = 0.59, p < 0.001, respectively). In contrast, there was no detectable association between fasting ghrelin levels and the ambient concentrations of glucagon or intact GLP-2.CONCLUSIONS: GLP-2 inhibits ghrelin secretion in humans at plasma levels of approximately 200 pmol/l. However, the physiological importance of this effect appears to be minor compared to the actions of insulin and glucose.

KW - Adult

KW - Blood Glucose

KW - C-Peptide

KW - Ghrelin

KW - Glucagon

KW - Glucagon-Like Peptide 2

KW - Humans

KW - Infusions, Intravenous

KW - Insulin

KW - Kinetics

KW - Male

KW - Peptide Hormones

U2 - 10.1016/j.regpep.2006.07.009

DO - 10.1016/j.regpep.2006.07.009

M3 - Journal article

C2 - 16928403

SN - 0167-0115

VL - 137

SP - 173

EP - 178

JO - Regulatory Peptides

JF - Regulatory Peptides

IS - 3

ER -

Glucagon-like peptide 2 inhibits ghrelin secretion in humans

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater